for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Moderna Inc

MRNA.O

Latest Trade

334.84USD

Change

0.00(0.00%)

Volume

42,872

Today's Range

--

 - 

--

52 Week Range

65.49

 - 

497.49

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
334.84
Open
0.00
Volume
42,872
3M AVG Volume
415.51
Today's High
--
Today's Low
--
52 Week High
497.49
52 Week Low
65.49
Shares Out (MIL)
403.65
Market Cap (MIL)
130,866.20
Forward P/E
11.05
Dividend (Yield %)
--

Next Event

Q3 2021 Moderna Inc Earnings Call

Latest Developments

更多

FDA Delays Moderna Covid-19 Vaccine For Adolescents To Review Rare Myocarditis Side Effect - WSJ

Moderna Inc Announces Covax Exercises Option To Purchase 176.5 Mln Additional Doses Of Moderna’S COVID-19 Vaccine For Low Income Countries

U.S. CDC ACIP To Meet On Oct. 20-21 To Discuss Covid-19 Vaccine Boosters For Modern, J&J

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Moderna Inc

Moderna, Inc. is a biotechnology company that is focused on creating a transformative medicines based on messenger RNA (mRNA). The Company’s mRNA medicines are designed to direct the body’s cells to produce intracellular, membrane, or secreted proteins that have a therapeutic or preventive benefit with the potential to address a range of spectrum of diseases. The Company develops technologies that enable the development of mRNA medicines for diverse applications. The Company has created modalities, including Prophylactic vaccines, Systemic secreted and cell surface therapeutics, Cancer vaccines, Intratumoral immuno-oncology, Localized regenerative therapeutics, and Systemic intracellular therapeutics. Its diverse development pipeline which consists of 27 development candidates across its 24 programs.

Industry

Biotechnology & Drugs

Contact Info

200 Technology Sq

Cambridge, MA

02139-3578

United States

+1.617.7146500

https://www.modernatx.com/

Executive Leadership

Noubar B. Afeyan

Non-Executive Independent Chairman of the Board, Co-Founder

Stephen Hoge

President

Stephane Bancel

Chief Executive Officer, Director

David Meline

Chief Financial Officer

Tracey Franklin

Chief Human Resources Officer

Key Stats

2.63 mean rating - 16 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2018

0.1K

2019

0.1K

2020

0.8K

2021(E)

20.2K
EPS (USD)

2018

-4.950

2019

-1.550

2020

-1.960

2021(E)

29.114
Price To Earnings (TTM)
40.47
Price To Sales (TTM)
18.64
Price To Book (MRQ)
19.49
Price To Cash Flow (TTM)
36.40
Total Debt To Equity (MRQ)
7.26
LT Debt To Equity (MRQ)
4.89
Return on Investment (TTM)
65.71
Return on Equity (TTM)
35.59

Latest News

Latest News

UPDATE 3-U.S. FDA delays decision on Moderna's COVID-19 vaccine for adolescents - WSJ

The U.S. health regulator is delaying its decision on authorizing Moderna Inc's COVID-19 vaccine for adolescents to check if the shot could increase the risk of a rare inflammatory heart condition, the Wall Street Journal reported on Friday.

U.S. FDA delays decision on Moderna's COVID-19 vaccine for adolescents - WSJ

The U.S. health regulator is delaying a decision on authorizing Moderna Inc's COVID-19 vaccine for adolescents to assess whether the shot may lead to heightened risk of heart inflammation, the Wall Street Journal reported on Friday, citing people familiar with the matter...

FACTBOX-Countries vaccinating children against COVID-19

Pfizer Inc and BioNTech SE have asked U.S. regulators to authorize their COVID-19 vaccine for emergency use in children aged 5-11, with an expert panel to the Food and Drug Administration scheduled to meet later this month to review data.

UPDATE 2-U.S. FDA advisers weigh case for booster shots of Moderna COVID-19 vaccine

Israel health officials on Thursday said booster doses of the Pfizer-BioNTech COVID-19 vaccine improved severe disease protection in people aged 40 and older, in presentations made to U.S. scientists discussing a booster dose of Moderna's vaccine.

UPDATE 2-J&J COVID-19 shot gets better boost from Moderna or Pfizer in NIH study

People who got Johnson & Johnson Inc’s COVID-19 vaccine as a first shot had a stronger immune response when boosted with vaccines from Pfizer Inc /BioNTech SE or Moderna Inc, a study run by the National Institutes of Health showed on Wednesday.

UPDATE 3-U.S. FDA staff says Moderna did not meet all criteria for COVID-19 boosters

Scientists at the U.S. Food and Drug Administration said on Tuesday that Moderna Inc had not met all of the agency's criteria to support use of booster doses of its COVID-19 vaccine, possibly because the efficacy of the shot's first two doses has remained strong.

Moderna's search for African site set to intensify - chairman

Rwanda, Senegal and South Africa could be potential locations for Moderna's planned vaccine factory in Africa, the U.S. drugmaker's co-founder and chairman said as it steps up its search for a site on the continent.

Moderna seeks COVID-19 vaccine booster clearance in older adults, high-risk individuals

Moderna Inc on Tuesday said the U.S. Food and Drug Administration should authorize booster doses of its COVID-19 vaccine in fully vaccinated older adults and other high-risk individuals.

UPDATE 1-U.S. CDC advisers to review Moderna, J&J COVID-19 booster shots this month

Independent advisers to the U.S. Centers for Disease Control and Prevention will meet later this month to make recommendations on booster doses of Moderna Inc and Johnson & Johnson's COVID-19 vaccines, the agency said on Friday.

U.S. CDC advisers to meet this month to discuss Moderna, J&J COVID-19 vaccine boosters

The U.S. Centers for Disease Control and Prevention's panel of vaccine advisers plans to meet on Oct. 20-21 to discuss COVID-19 vaccine boosters using Moderna and Johnson & Johnson shots, an agency spokesperson said on Friday.

UPDATE 1-Moderna aims to deliver 1 bln more vaccine doses to low-income countries in 2022

Moderna Inc said on Friday it aims to deliver one billion doses of its COVID-19 vaccine to low-income countries in 2022, in addition to the doses it has already committed to the global vaccine-sharing platform COVAX.

Moderna to deliver another 1 bln vaccine doses to low-income countries next year

Moderna Inc said on Friday it was looking to deliver another 1 billion doses of its COVID-19 vaccine to low-income countries in 2022. (Reporting by Manojna Maddipatla in Bengaluru; Editing by Saumyadeb Chakrabarty)

UPDATE 1-Denmark says Moderna vaccine remains available to under-18s

The Danish Health Agency said on Friday that it was continuing to offer Moderna's COVID-19 vaccine to under-18s, and that a statement on Wednesday suggesting a suspension had in fact been a miscommunication.

UPDATE 4-Moderna plans African vaccine plant as drugmakers urged to help poorest

* Moderna to invest up to $500 mln in plant, location undecided

UPDATE 2-Finland joins Sweden and Denmark in limiting Moderna COVID-19 vaccine

Finland on Thursday paused the use of Moderna's COVID-19 vaccine for younger males due to reports of a rare cardiovascular side effect, joining Sweden and Denmark in limiting its use.

Finland pauses use of Moderna COVID-19 vaccine in young men

Finland will pause the use of Moderna's COVID-19 vaccine for men born in 1991 and later due to reports of a rare cardiovascular side effect, the institute for health and welfare said on Thursday.

Moderna plans mRNA vaccine factory in Africa

Moderna plans to invest about $500 million to build a factory in Africa to make up to 500 million doses of mRNA vaccines each year, it said on Thursday.

UPDATE 3-EU regulator backs mRNA vaccine booster for people with weak immunity

* Booster shot for all after 6 months may be considered (Adds comment from academic, background)

Sweden to give 12-15 year olds Pfizer vaccine, rejects Moderna

Sweden's Public Health Agency said on Monday it recommended the use of Pfizer-BioNTech's , Comirnaty vaccine against COVID-19 for children between 12-15, opting against rival Moderna's Spikevax.

UPDATE 1-Heart inflammation rates higher after Moderna COVID-19 vaccine - Canada data

Canadian health officials said on Friday data suggests reported cases of rare heart inflammation were relatively higher after Moderna's COVID-19 vaccine compared with the Pfizer/BioNTech shots .

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up